The clinical significance of gelatinase B in gouty arthritis of the knee

Clinica Chimica Acta

Volumn 339, Issue 1-2, 2004, Pages 77-83

  Chu, Shu Chen ^a   Yang, Shun Fa ^b   Lue, Ko Huang ^b   Hsieh, Yih Shou ^b   Hsiao, Tang Yan ^c   Lu, Ko Hsiu ^b,c  

^a CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Gouty arthritis; Inflammation; MMP 2; MMP 9; Neutrophils

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRITIS; ARTICLE; CELL COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ANALYSIS; FEMALE; GOUT; HUMAN; KNEE; KNEE ARTHRITIS; LABORATORY; MALE; NEUTROPHIL; PATIENT; PRIORITY JOURNAL; SAMPLE; SCORING SYSTEM; SYNOVIAL FLUID LEVEL; ZYMOGRAPHY;

EID: 0346366553     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.09.008     Document Type: Article

References (34)

1. McCarty D.J., Kohn N.N., Faires J.S. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the pseudogout syndrome: I. Clinical aspects. Ann. Intern. Med. 56:1962;711-737.
2. Dieppe P.A., Crocker P.R., Corke C.F., Doyle D.V., Huskisson E.C., Willoughby D.A. Synovial fluid crystals. QJM. 48:1979;533-553.
3. Terkeltaub R. Gout: crystal-induced inflammation. Gallin J.I., Goldstein I.M., Snyderman R. Inflammation: basic principles and clinical correlates. 1992;977-981 Raven Press, New York.
4. Guerne P.A., Terkeltaub R., Zuraw B., Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 32:1989;1443-1452.
5. Terkeltaub R., Zachariae C., Santoro D., Martin J., Peveri P., Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum. 34:1991;894-903.
6. di Giovine F.S., Malawista S.E., Thornton E., Duff G.W. Urate crystals stimulate production of tumor necrosis factor α from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular distribution. J. Clin. Invest. 87:1991;1375-1381.
7. Hembry R.M., Dyce J., Driesang I., Hunziker E.B., Fosang A.J., Tyler J.A.et al. Immunolocalization of matrix metalloproteinases in partial-thickness defects in pig articular cartilage. A preliminary report. J. Bone Joint Surg. Am. 83:2001;826-838.
8. Opdenakker G., Masure S., Grillet B., Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 10:1991;317-324.
9. Hirose T., Reife R.A., Smith G.N., Stevens R.M., Mainardi C.L., Hasty K.A. Characterization of type V collagenase (gelatinase) in synovial fluid of patients with inflammatory arthritis. J. Rheumatol. 19:1992;593-599.
10. Koolwijk P., Miltenburg A.M., van Erck M.G., Oudshoorn M., Niedbala M.J., Breedveld F.C.et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J. Rheumatol. 22:1995;385-393.
11. Lu KH, Yang SF, Chu SC, Chen PN, Chou MC, Hsiao TY, et al. The significance of altered expressions of gelatinases in the synovium of patient with arthritic effusions. Clin. Rheumatol. (in press).
12. Hsieh YS, Yang SF, Chu SC, Chen PN, Chou MC, Hsu MC, et al. Expression changes of gelatinases in human osteoarthritic knee and the arthroscopic débridement. Arthroscopy (in press).
13. Makowski G.S., Ramsby M.L. Zymographic analysis of latent and activated forms of matrix metalloproteinases-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin. Chim. Acta. 329:2003;77-81.
14. Miltenburg A.M., van Laar J.M., de Kuiper R., Daha M.R., Breedveld F.C. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation. Br. J. Rheumatol. 30:1991;186-199.
15. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218:1994;325-329.
16. Kuo W.H., Chou F.P., Lu S.C., Chu S.C., Hsieh Y.S. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Clin. Chim. Acta. 294:2000;157-168.
17. Fini M.E., Cook J.R., Mohan R., Brinckerhoff C.E. Regulation of matrix metalloproteinase gene expression. Parks W.C., Mecham R.P. Matrix metalloproteinases. 1998;300-356 Academic, California.
18. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:1990;121-125.
19. Hembry R.M., Bagga M.R., Reynolds J.J., Hamblen D.L. Immunolocalization studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovial from patients with osteo- and rheumatoid arthritis. Ann. Rheum. Dis. 54:1995;25-32.
20. Nagase H., Okada Y. Proteinases and matrix degradation. Kelly W.N., Harris E.D. Jr., Ruddy S., Sledge C.B. The textbook of rheumatology. 5th ed. 1996;323-341 Saunders, Philadelphia.
21. Ahrens D., Koch A.E., Pope R.M., Stein-Picarella M., Niedbala M.J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 39:1996;1576-1587.
22. Grillet B., Dequeker J., Paemen L., Van Damme B., Opdenakker G. Gelatinase B in synovitis: immunolocalization with a monoclonal antibody. Br. J. Rheumatol. 36:1997;744-747.
23. Zhang Y., McCluskey K., Fujii K., Wahl L.M. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanism. J. Immunol. 161:1998;3071-3076.
24. Pugin J., Widmer M.C., Kossodo S., Liang C.M., Preas H.L. II, Suffredini A.F. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am. J. Respir. Cell Mol. Biol. 20:1999;458-464.
25. Supuran C.T., Scozzafava A. Matrix metalloproteinases (MMPs). Smith H.J., Simons C. Proteinase and peptidase inhibition: recent potential targets for drug development. 2002;35-61 Taylor & Francis, London.
26. Masure S., Proost P., Van Damme J., Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198:1991;391-398.
27. Clegg P.D., Burke R.M., Coughlan A.R., Riggs C.M., Carter S.D. Characterization of equine matrix-metalloproteinase 2 and 9 and identification of the cellular sources of these enzymes in joints. Equine. Vet. J. 29:1997;335-342.
28. Clegg P.D., Coughlan A.R., Riggs C.M., Carter S.D. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine. Vet. J. 29:1997;343-348.
29. Coughlan A.R., Robertson D.H., Bennett D., May C., Beynon R.J., Carter S.D. Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet. Rec. 143:1998;219-223.
30. Nagase H. Matrix metalloproteinases. Koide H., Hayashi T. Extracellular matrix in the kidney. 1994;85-93 S Karger AG, Basel.
31. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop. Scand. Suppl. 266:1995;55-60.
32. Supuran C.T., Casini A., Scozzafava Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory and antiviral agents. Med. Res. Rev. 23:2003;535-558.
33. Gay S., Gay R.E., Koopman W.J. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann. Rheum. Dis. 52:1993;S39-S47.
34. Tak P.P., Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 43:2000;2619-2633.